| Document Date: 2014-05-12 19:51:02
Open Document File Size: 641,52 KBShare Result on Facebook
City South San Francisco / Nashville / San Antonio / Chicago / / Company AEs / TX 2Genentech Inc. / Infante3 1South Texas Accelerated Research Therapeutics LLC. / Genentech / / Event FDA Phase / / MedicalCondition tumor / Ovarian cancer / pneumonia / drug hypersensitivity / cancer / lymphoma / disease / neutropenia / Nausea / carcinoma / Vomiting / SCLC / fatigue / study discontinuation Disease / stable disease / MALT lymphoma / No Bell’s palsy / Refractory Solid Tumors / pruritus / pneumonitis / rash / breast cancer / anemia / Primary tumor / 24HR Timepoint Tumor / / MedicalTreatment Surgery / / MusicGroup Nausea / / Organization CA 3Sarah Cannon Research Institute / / Position study discontinuation Disease progression Adverse event Physician / / Product GDC-0917 / / ProvinceOrState Tennessee / / Technology Pharmacokinetics / Chemotherapy / pharmacodynamics / Apoptosis / / |
1 Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma